Abstract
We thank the authors of both editorials for their insightful commentary regarding our report. We agree that the ultimate goal should be to preoperatively recognize these select patients with high Gleason sum prostate cancer and favorable surgical outcomes. Additional studies of the clinical parameters, molecular markers, and imaging technologies are needed to accurately identify these men.
Accepted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
